$2 billion heavyweight partnership finalized! Under the AI-driven pharmaceutical trend, Chinese innovation becomes the core focus for multinational pharmaceutical companies.

Question AI · Eli Lilly makes a hefty bet on Insilico Intelligence—what technical breakthroughs in China’s AI-driven drug discovery does it highlight?

As the global pharmaceutical industry finds itself trapped in a dilemma of long R&D cycles, high capital costs, and sluggish success rates, artificial intelligence is becoming the core key to break the impasse. Chinese AI-driven drug discovery companies have already stepped onto the center stage of this new round of industrial transformation. At the end of March 2026, Eli Lilly, a U.S. pharmaceutical giant, reached an exclusive AI drug discovery collaboration with Insilico Medicine, a company listed on Hong Kong stocks, worth over $2 billion. With a $115 million upfront payment, Lilly locked in global rights for Insilico’s GLP-1 oral blood-sugar-lowering drug. This blockbuster deal not only sets a record for the scale of collaboration in the AI drug discovery sector, but also becomes a clear signal: since 2025, the number of overseas licensing authorizations for China’s innovative drugs has repeatedly hit historical highs. The global pharmaceutical industry’s reliance on China’s R&D strength is continuing to deepen. A paradigm shift in drug R&D driven by AI and led by China’s innovative participation is now thoroughly rewriting the competitive and collaborative landscape of the global pharmaceutical industry.

On March 30, 2026, reporting on the collaboration between Eli Lilly and Insilico Intelligence disclosed the details behind this blockbuster AI drug discovery transaction, confirming that it has fully taken shape. Under the agreement, Eli Lilly will obtain the worldwide exclusive sales rights for GLP-1 diabetes drugs developed by Insilico Medicine using artificial intelligence. The transaction includes a $115 million upfront payment. If regulatory approvals and sales performance milestones are achieved thereafter, the total amount could reach up to $2.75 billion. Eli Lilly had already become a shareholder of Insilico when Insilico completed its Hong Kong IPO in late 2025 as an anchor investor. The two parties’ ties have long gone beyond an ordinary commercial collaboration, becoming a typical example of deep linkage between a multinational pharmaceutical company and a Chinese AI-driven drug discovery enterprise.

This collaboration is by no means an incidental capital romance, but rather an inevitable outcome as the global AI drug discovery industry enters a commercialization-and-realization phase. For a long time, traditional new drug R&D has been likened to a combination of “burning money and taking risks.” From target discovery to final上市, an innovative drug often takes more than ten years and requires R&D investment exceeding $1 billion, while the failure rate in clinical stages remains notoriously high—one of the common challenges faced by pharmaceutical companies worldwide. The introduction of AI has completely overturned this traditional pathway. Through big-data algorithms and model iteration, AI can significantly shorten the timelines for selecting drug molecules and validating targets, while simultaneously reducing R&D costs and failure risks. As a leading AI drug discovery pioneer listed on Hong Kong stocks, Insilico Intelligence relies on its independently developed AI platform to compress the GLP-1 drug R&D cycle to one-third of that of the traditional model. Moreover, its focus on oral dosage forms directly addresses a key industry pain point: poor patient adherence to current mainstream GLP-1 injection drugs. This is also the core logic behind Eli Lilly’s willingness to secure the rights at great expense. For Eli Lilly, this deal is a critical move to consolidate its dominant position in metabolic disease and to fend off competitive pressure from peers. It is also the ultimate recognition of China’s AI drug discovery technology—from proof of concept to commercialization potential.

Looking at the global pharmaceutical market, the cooperation between Eli Lilly and Insilico Intelligence is only a snapshot of the wave of Chinese innovative drugs “going global” since 2025. Data show that in 2025, the number of drug licenses granted to overseas partners by global pharmaceutical companies from Chinese companies hit a historical record. Regardless of number, transaction value, or collaboration tier, China’s innovative drug overseas licensing deals achieved a qualitative leap. They have completely shaken off the past position of being mere supporting roles focused on contract manufacturing and technology following, and instead have become a core supplier of global pharmaceutical innovation. Previously, collaborations between multinational pharmaceutical companies and Chinese pharmaceutical companies mainly concentrated on late-stage clinical projects or regional licensing for mature products. Now, cooperation has shifted early to core areas such as AI drug discovery platforms and joint development of early innovative pipelines. Companies including CSPC, Huasheng Smart Pharmaceutical, and others in China have consecutively secured overseas authorizations worth tens of billions of dollars. The collaboration areas have also rapidly expanded from traditional oncology tracks to blue-ocean markets such as metabolic diseases and autoimmune diseases.

Behind this surge in outbound expansion lies the full-chain maturation and rise of China’s AI drug discovery industry. At the policy level, the integration and innovation of biomedicine and artificial intelligence has been listed as a national strategic direction in science and technology. From R&D support and knowledge property protection to providing support for innovative drug companies through the capital markets, a series of policies has cleared development obstacles for AI drug discovery companies. At the technical level, China’s integration of AI large models with drug R&D is at the forefront globally. Key steps such as target discovery, molecular design, and clinical prediction continue to break new ground, forming a distinctive AI drug discovery technology system with clear advantages. At the industrial level, abundant domestic clinical resources and a mature CRO/CDMO supporting ecosystem create an efficient closed loop with AI R&D. This enables China’s innovative drugs to achieve rapid deployment from the lab to commercialization, while also letting multinational pharmaceutical companies see the core value of China’s R&D.

The R&D map of the global pharmaceutical industry is being quietly reshaped by the rise of China’s AI innovation strength. Today, all global Top 20 multinational pharmaceutical companies have already laid out AI drug discovery tracks. AI has evolved from a research-assistance tool into a standard feature of drug companies’ core competitiveness, and the industry has entered an arms race stage centered on efficiency. Meanwhile, the collaboration model between multinational pharmaceutical companies and Chinese pharmaceutical companies has shifted from simple technology procurement and product licensing to deep binding through equity investment, joint R&D, risk sharing, and benefit sharing. Eli Lilly’s early move into Insilico Intelligence’s equity is a vivid demonstration of this new cooperation model. The global center of pharmaceutical innovation is gradually moving eastward: China is no longer just a manufacturing link in the global pharmaceutical industry chain, but is becoming one of the core sources of innovative R&D.

Of course, despite the opportunities, challenges should not be overlooked. Clinical data validation standards for AI drug discovery have not yet been fully unified. Potential risks still exist regarding multinational data compliance and knowledge property disputes. Global R&D competition in hot tracks such as GLP-1 is growing increasingly fierce. For China’s AI drug discovery companies to continue standing firm in the global market, they still need to keep digging deep in areas such as technology iteration, clinical translation, and commercialization deployment. But it is undeniable that the cooperation between Eli Lilly and Insilico Intelligence has already become an important milestone for global pharmaceutical innovation. It signifies that China’s AI drug discovery has officially entered the global core stage, and it also suggests that future global pharmaceutical innovation will be shaped by a new landscape of complementary strengths and coexistence of competition and collaboration between China and abroad.

In the wave of innovation where technology knows no borders, Chinese AI drug discovery enterprises have, with hard-core strength, broken the long-standing R&D pattern dominated by multinational pharmaceutical companies. This is not only a leapfrog breakthrough for China’s healthcare industry, but also an important step for the global pharmaceutical industry to move toward a more efficient and more widely accessible era. With continued iteration of AI technologies and deeper industrial collaborations, China’s innovative drugs will achieve breakthroughs in more disease areas, writing more innovation stories belonging to China in the global pharmaceutical market.